|Videos|December 13, 2022
COSMIC-313 and Advice to Community Oncologists Treating Advanced RCC
Author(s)Eric Jonasch, MD
Dr Eric Jonasch reviews key efficacy outcomes from the COSMIC 313 trial, its clinical implications, and shares advice for community oncologists treating patients with advanced renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5